Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer

Efficacy and safety of sorafenib in patients with advanced renal cancer were evaluated. Seventy-four patients with advanced renal cancer treated with sorafenib + interferon from January 2010 to August 2013 were included as the observation group. Another 53 renal cancer patients treated with interfer...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2019-02, Vol.17 (2), p.1547-1550
Main Authors: Qiu, Juhui, Liu, Dongjian, Yan, Zaichun, Jiang, Wei, Zhang, Qinglei, Li, Ning, Deng, Wentao, Ding, Kejia
Format: Article
Language:English
Subjects:
Age
Alopecia
Antineoplastic agents
Biological response modifiers
Cancer patients
Cancer therapies
Cancer treatment
Complications and side effects
Diarrhea
Disease control
Drug dosages
Drug therapy
Hypertension
Inhibitor drugs
Interferon
Kidney cancer
Liver
Males
Medical prognosis
Metastasis
Oncology
Operating systems (Software)
Patients
Public relations
Rash
Response rates
Skin
Sorafenib
Survival analysis
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efficacy and safety of sorafenib in patients with advanced renal cancer were evaluated. Seventy-four patients with advanced renal cancer treated with sorafenib + interferon from January 2010 to August 2013 were included as the observation group. Another 53 renal cancer patients treated with interferon alone were included in the control group. Clinical data of those patients were retrospectively analyzed. Treatment plan: initial dose was 400 mg, twice a day. Additionally, patients in the interferon group were treated with another 300 MU every other day. Efficacy was evaluated according to RECIST criteria, and progression-free survival (PFS), overall survival (OS), and incidence of adverse reactions were recorded. In the observation group, a median OS was 15.3 months (range, 9-60 months), and a median PFS was 8.2 months (range, 2-36 months). There were 4 cases of complete remission (CR) (5.41%), 16 cases of partial remission (PR) (21.62%), 42 cases of stable disease (SD) (56.76%), 12 cases of disease progression (16.22%), and disease control rate (DCR) was 83.78% (62 cases). In the control group, median OS time was 12.5 months (range, 8-60 months), and the median PFS time was 9.3 months (range, 2-40 months). There were 2 cases of CR (3.77%), 11 cases of PR (20.75%), 20 cases of SD (37.74%), 20 cases of disease progression (37.74%), and DCR was 62.26% (33 cases). Disease control rate in the observation group was significantly higher than that in the control group (P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.9776